Reducing sedentary behavior in patients with chronic kidney disease and obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The Sit Less, Interact and Move More (SLIMM) 2 study aims to address the negative health impacts of prolonged sitting in individuals with chronic kidney disease and obesity. This interventional study will evaluate the effectiveness of guided resistance training combined with semaglutide, a medication approved for diabetes and weight loss, to enhance adherence to a program designed to reduce sedentary behavior. Participants will be monitored for changes in physical activity levels and overall health outcomes. The study is being conducted at the University of Utah and Stanford University.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Glomerular Filtration Rate (eGFR) 20 to \<60 mL/min/1.73m\^2
* Able to perform resistance training
* Access to compatible "smartphone" or device (i.e., Android, Kindle or Apple with internet connectivity or mobile network), desktop or laptop

Exclusion Criteria:

* Type 1 Diabetes
* History of gastroparesis or paralytic ileus
* At baseline, if sedentary time is 25 min/hr or less, measured by accelerometer
* Potential contraindications to semaglutide such as a history of pancreatitis, and a family or personal history of multiple endocrine neoplasia type 2 or familial medullary thyroid carcinoma.
* Previous bariatric surgery
* Medical condition likely to limit survival to less than 1 year
* Anticipated start of dialysis or kidney transplantation within 6 months
* Any factors judged by the investigator or study team to likely limit adherence to interventions
* Vulnerable populations- pregnant or incarcerated
* Enrolled in interventional trials using drugs or devices
* Not able to undergo informed consent
* Recent hospitalizations or major interventional procedures done within the past 60 days
* Known or suspected hypersensitivity to tegaderm
* Use of any GLP-1 receptor agonist within 30 days prior to screening
* Presently classified as being in New York Heart Association (NYHA) Class IV Heart Failure
* Daytime use of supplemental oxygen (i.e., prescribed a stationary or portable oxygen system)
* Presence of metastatic cancer
* Current use of mobility aid(s)
* Living in the same household of a participant already enrolled in the study

Where it's running

• Stanford University
  Stanford, California, United States Recruiting
• University of Utah
  Salt Lake City, Utah, United States Recruiting

Study contacts

• Principal investigator: Srinivasan Beddhu, M.D. — University of Utah
• Study coordinator: Amara Sarwal, M.D.
• Email: Amara.Sarwal@hsc.utah.edu
• Phone: 801-585-9815

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding chronic kidney disease in Sub-Saharan Africa

  This study is trying to understand how common chronic kidney disease is in Sub-Saharan Africa and what factors might be causing it by looking at the health and lifestyle of adults in the Bagamoyo district.

  Recruiting Swiss Tropical & Public Health Institute · Bagamoyo, Pwani Region · NCT05881447

• Understanding risk factors for chronic kidney disease linked to metabolic diseases

  This study is trying to find out how conditions like high blood pressure, diabetes, and obesity can lead to kidney problems in people with chronic kidney disease.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT05476627

• Research on health inequality and genetic disparity in cardiovascular diseases

  This study is trying to understand how health differences and genetics affect heart diseases in people from various ethnic backgrounds in the UK to help improve treatments for everyone.

  Recruiting Future Genetics Limited · Wolverhampton, West Midlands · NCT03987633

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.